ArticleBMC gastroenterology2026
Serum aberrant expression of miR-331-3p and its diagnostic value in severe pancreatitis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute pancreatitis (SAP) is characterized by persistent organ failure and a high mortality rate, early diagnosis and disease assessment are crucial for improving patient prognosis.
aimsTo investigate the expression level, diagnostic value, and mechanism of action of serum miR-331-3p in patients with SAP.
methodsOne hundred eighty-five patients with AP (including 130 patients with mild-to-moderate acute pancreatitis (MAP) and 55 patients with SAP) and 100 healthy controls (HC) were enrolled. RT-qPCR was conducted to detect the expression of serum miR-331-3p, and its diagnostic efficacy was analyzed using receiver operating characteristic (ROC) curves. Correlation analysis was carried out using the Pearson correlation coefficient. The molecular mechanism was explored by combining dual-luciferase reporter gene assay and cell function experiments.
resultsThe level of serum miR-331-3p expression in the SAP group was markedly lower than that in the MAP and HC groups (P < 0.05). The AUC for distinguishing MAP from SAP was 0.866 (95% CI: 0.810–0.921), with a sensitivity of 83.6% and a specificity of 73.1%. miR-331-3p was strongly negatively correlated with SAP routine indicators, severity, and inflammation (P < 0.001). Mechanistically, miR-331-3p directly targets bromodomain protein 4 (BRD4), and the overexpression of miR-331-3p alleviate the inflammatory response in the SAP cell model and promote cell proliferation, whereas BRD4 overexpression reversed the effects of miR-331-3p.
conclusionsSerum miR-331-3p is notably downregulated in SAP and may attenuate pancreatic inflammation through BRD4 targeting and inhibition, proposing its candidacy as a diagnostic biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.